Atyr PHARMA (NASDAQ:ATYR – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Profitability
This table compares Atyr PHARMA and Qiagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atyr PHARMA | N/A | -79.44% | -59.16% |
| Qiagen | 4.23% | 13.92% | 8.40% |
Insider & Institutional Ownership
61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atyr PHARMA | $235,000.00 | 1,214.48 | -$50.39 million | ($0.94) | -3.62 |
| Qiagen | $1.98 billion | 4.46 | $83.59 million | $0.36 | 110.44 |
Qiagen has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Atyr PHARMA has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Atyr PHARMA and Qiagen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atyr PHARMA | 0 | 0 | 6 | 1 | 3.14 |
| Qiagen | 0 | 7 | 3 | 0 | 2.30 |
Atyr PHARMA presently has a consensus target price of $18.60, indicating a potential upside of 447.06%. Qiagen has a consensus target price of $47.71, indicating a potential upside of 20.00%. Given Atyr PHARMA’s stronger consensus rating and higher probable upside, equities analysts clearly believe Atyr PHARMA is more favorable than Qiagen.
Summary
Qiagen beats Atyr PHARMA on 9 of the 15 factors compared between the two stocks.
About Atyr PHARMA
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.
